Viking Therapeutics stock, in contrast, might dodge a bullet on this news. And why? As CNBC reports today, the Biden administration is using its last few days in office to add 15 prescription ...

Wednesday, Goldman Sachs initiated coverage on Viking Holdings (NYSE:VIK) stock, a $20.9 billion market cap cruise operator, with a Neutral rating and a 12-month price target of $49.00. The firm's ...

Wall Street's consensus price target of $110 implies more than 220% upside to Viking stock. Wall Street has high hopes for development-stage pharmaceutical company Viking Therapeutics. Medications ...

As of 11 a.m. ET, shares of Novo Nordisk (NYSE: NVO) are down 4.2%, and Hims & Hers Health (NYSE: HIMS) stock is getting walloped for a 5.8% loss. In contrast, shares of Viking Therapeutics ...

It's been a volatile year for Viking Therapeutics stock, though good news on the weight-loss-drug front has the healthcare stock up 260% since the start of January. And Wall Street sees even more ...

In the latest market close, Viking Therapeutics, Inc. (VKTX) reached $38.88, with a -1.09% movement compared to the previous day. The stock's change was less than the S&P 500's daily gain of 0.16%.

Is that price target realistic? Should you buy Viking Therapeutics stock before it goes to the moon? Wall Street is bullish on Viking, but the company still has a lot to prove Viking has a number ...